Marvel Biosciences Corp. MBCOF
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.53% | -4.36% | -0.90% | -0.50% | -5.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.93% | -4.86% | 46.32% | 18.38% | -33.55% |
| Operating Income | -1.93% | 4.86% | -46.32% | -18.38% | 33.55% |
| Income Before Tax | 13.04% | -25.17% | -58.07% | -31.35% | 25.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.04% | -25.17% | -58.07% | -31.35% | 25.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.04% | -25.17% | -58.07% | -31.35% | 25.94% |
| EBIT | -1.93% | 4.86% | -46.32% | -18.38% | 33.55% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.25% | 0.35% | -28.06% | -7.59% | 31.55% |
| Normalized Basic EPS | 12.50% | 0.56% | -28.48% | -6.84% | 31.71% |
| EPS Diluted | 28.25% | 0.35% | -28.06% | -7.59% | 31.55% |
| Normalized Diluted EPS | 12.50% | 0.56% | -28.48% | -6.84% | 31.71% |
| Average Basic Shares Outstanding | 30.44% | 24.41% | 20.18% | 17.19% | 9.88% |
| Average Diluted Shares Outstanding | 30.44% | 24.41% | 20.18% | 17.19% | 9.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |